Thorough and intensive QTc Studies

Richmond Pharmacology has globally recognised expertise in cardiac safety, intensive ECG studies, cardiology overreading, statistical analysis, reporting and publishing.

We are proud of our successful track record which is demonstrated in our published studies.

We provide sponsors with FDA compliant analysis methods, and the option to include a non-pharmacological method of proving assay sensitivity. Our unique and innovative approach means that we conduct our studies and prove assay sensitivity as a standard feature. This has provided quality data in many Japanese bridging, SAD and MAD studies, eliminating the need for a dedicated TQT study.

x

Examples of our credentials in TQT and QTc Studies

Food effect on QT interval. Our research has confirmed food impacts cardiac repolarisation by shortening the J-T peak. This can be used in our studies as a non-pharmacological method of proving assay sensitivity. Learn more here.

Sex hormones and the QT Interval. Research funded by Richmond Pharmacology identified a significant influence of estradiol on QTcF suggesting a menstrual cycle could influence the QTc. Learn more here.

Short start-up times of 4-6 weeks, rapid data readout

Our study data is well respected by regulators such as FDA, EMA and PMDA. Our statistical team specialise in statistical analysis concentration effect modelling, reporting, and publishing.

Get in touch today

Why choose Richmond Pharmacology for TQT & QTc Studies

TAP OR CLICK A BLOCK BELOW TO LEARN MORE

Low data variability

Our core ECG laboratory provides a centralised system for all our studies.

Read more +

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment.

Read more +

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London.

Read more +

Our in-house cardiac experts include Professor John Camm and Dr Jorg Taubel. Together, they ensure your QTc study is best-in-class. Meet the team.

Latest news

Samarjit Singh promoted to New Director of Clinical Operations

August 30, 2022
Richmond Pharmacology is delighted to announce the promotion of Samarjit Singh into the position of Director of Clinical Operations.
Read more

Transforming clinical trials to accelerate drug development – Keith Berelowitz

August 23, 2022
Dr Keith Berelowitz, Richmond Pharmacology’s Director of Operations, wrote recently for Pharmaceutical Market Europe where he outlined how innovations in the design and delivery of clinical trials are speeding up the discovery of new therapies for the benefit of patients, sponsors and health systems.
Read more

Events

The Future of Healthcare - March 2022

13:30 – 16:00, 22nd March 2022
Discover the intricacies of assessing abnormal liver functions in clinical trial volunteers and gain insights from the latest drug development trials using RNAi therapeutics.
View event